Detalhe da pesquisa
1.
Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice.
Gut;
65(12): 2029-2034, 2016 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26306759
2.
Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in vitro resistance to SR-BI-targeting agents.
Hepatology;
60(5): 1508-18, 2014 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24797654